These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 825327)

  • 21. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.
    Pierpont GL; Cohn JN; Franciosa JA
    Chest; 1978 Jan; 73(1):8-13. PubMed ID: 620563
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of the effects of dopamine, hydralazine, and isosorbide dinitrate on myocardial hemodynamics in patients with refractory heart failure.
    Biddle TL; Moses HW
    J Clin Pharmacol; 1981; 21(8-9):343-50. PubMed ID: 7276228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure.
    Massie B; Kramer B; Haughom F
    Circulation; 1981 Mar; 63(3):658-64. PubMed ID: 6780233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.
    Franciosa JA; Pierpont G; Cohn JN
    Ann Intern Med; 1977 Apr; 86(4):388-93. PubMed ID: 848799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained effect of hydralazine in long term treatment of CHF.
    Conradson TB; Rydén L
    Acta Med Scand Suppl; 1981; 652():173-6. PubMed ID: 6800217
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure.
    Chirkov YY; De Sciscio M; Sverdlov AL; Leslie S; Sage PR; Horowitz JD
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):131-7. PubMed ID: 20490904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
    Shah PK; Amin DK; Hulse S; Shellock F; Swan HJ
    Circulation; 1985 Feb; 71(2):326-31. PubMed ID: 3155500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure.
    Magorien RD; Brown GP; Unverferth DV; Nelson S; Boudoulas H; Bambach D; Leier CV
    Circulation; 1982 Mar; 65(3):528-33. PubMed ID: 7055874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of effectiveness of dihydralazine in the long-term treatment of chronic heart failure.
    Reifart N; Kaltenbach M; Bussmann WD
    Eur Heart J; 1984 Jul; 5(7):568-80. PubMed ID: 6479183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydralazine in chronic CHF.
    Chatterjee K; Rouleau JL; Massie BM
    Acta Med Scand Suppl; 1981; 652():99-113. PubMed ID: 6949469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy.
    Unverferth DV; Mehegan JP; Magorien RD; Unverferth BJ; Leier CV
    Am J Cardiol; 1983 May; 51(8):1392-8. PubMed ID: 6682617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects.
    Artman M; Parrish MD; Boerth RC; Boucek RJ; Graham TP
    Circulation; 1984 May; 69(5):949-54. PubMed ID: 6705171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension.
    Groves BM; Rubin LJ; Frosolono MF; Cato AE; Reeves JT
    Am Heart J; 1985 Dec; 110(6):1200-4. PubMed ID: 3907315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early and medium term results of tailored therapy for heart failure.
    Martins S; Soares RM; do Rosário L; Quininha J; Antunes AM
    Rev Port Cardiol; 2001 Mar; 20(3):261-82. PubMed ID: 11417309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.
    Rubin SA; Chatterjee K; Ports TA; Gelberg HJ; Brundage BH; Parmley WW
    Am J Cardiol; 1979 Nov; 44(6):1183-9. PubMed ID: 495513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency.
    Greenberg BH; DeMots H; Murphy E; Rahimtoola S
    Circulation; 1980 Jul; 62(1):49-55. PubMed ID: 7379285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oral hydralazine on rest and exercise hemodynamics in patients with aortic or mitral regurgitation and left ventricular dysfunction.
    Slosky DA; Hindman MC; Peter RH; Wallace AG
    Clin Cardiol; 1981; 4(4):162-7. PubMed ID: 7273499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses.
    Magorien RD; Unverferth DV; Leier CV
    Am J Med; 1984 Aug; 77(2):267-74. PubMed ID: 6431812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.
    Fitzgerald DJ; O'Callaghan WG; O'Malley K; Horgan J; O'Brien E
    Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):217S-222S. PubMed ID: 6753903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale.
    Rubin LJ; Peter RH
    Am J Cardiol; 1981 Jan; 47(1):116-22. PubMed ID: 7457397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.